肿瘤乏氧分子靶向治疗

国际肿瘤学杂志››2014,Vol. 41››Issue (5): 327-331.doi:10.3760/cma.j.issn.1673-422X.2014.05.003

李姗姗,邢力刚,孙晓蓉

250117 济南大学 betway.com 医学与生命科学学院;山东省肿瘤医院放疗科（李姗姗、邢力刚），PET-CT中心（孙晓蓉）

收稿日期:2013-11-18修回日期:2014-01-15出版日期:2014-05-08发布日期:2014-04-28
通讯作者:邢力刚 E-mail:xinglg@medmail.com.cn
基金资助:

国家自然科学基金（81001004）；山东省自然科学基金（ZR2010HL027）

Molecular targeted therapy of tumor hypoxia

Li Shanshan, Xing Ligang, Sun Xiaorong

School of Medical and Life Sciences， University of Ji′nan-Shandong Academy of Medical Sciences； Department of Radiation Oncology, Shandong Cancer Hospital, Ji′nan 250117, China

Received:2013-11-18Revised:2014-01-15Online:2014-05-08Published:2014-04-28
Contact:Xing Ligang E-mail:xinglg@medmail.com.cn

摘要/Abstract

摘要：乏氧是多数实体瘤的固有特征之一，可增加肿瘤细胞对放化疗的耐受性、促使肿瘤血管生成，是重要的不良预后因素。靶向杀伤肿瘤内的乏氧细胞成为肿瘤治疗的热点。生物还原性药物可通过特定的还原反应激活为细胞毒性代谢产物进而杀伤乏氧肿瘤细胞，而小分子靶点抑制剂则选择性地作用于乏氧途径中的关键环节，二者为肿瘤的乏氧靶向治疗开辟了新的途径。

李姗姗,邢力刚,孙晓蓉. 肿瘤乏氧分子靶向治疗[J]. 国际肿瘤学杂志, 2014, 41(5): 327-331.

Li Shanshan, Xing Ligang, Sun Xiaorong. Molecular targeted therapy of tumor hypoxia[J]. Journal of International Oncology, 2014, 41(5): 327-331.

［1］ Wilson WR, Hay MP. Targeting hypoxia in cancer therapy［J］. Nat Rev Cancer, 2011, 11(6): 393-410. ［2］ Nishida CR, Lee M, de Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1［J］. Mol Pharmacol, 2010, 78(3):497-502. ［3］ Williams KJ, Albertella MR, Fitzpatrick B, et al. In vivo activation of the hypoxiatargeted cytotoxin AQ4N in human tumor xenografts［J］. Mol Cancer Ther, 2009, 8(12):3266-3275. ［4］ Papadopoulos KP, Goel S, Beeram M, et al. A phase 1 openlabel, accelerated doseescalation study of the hypoxiaactivated prodrug AQ4N in patients with advanced malignancies［J］. Clin Cancer Res, 2008, 14(21):7110-7115. ［5］ Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase Ⅰ study［J］. Ann Oncol, 2007, 18(6):1098-1103. ［6］ Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells［J］. Expert Opin Investig Drugs, 2009, 18 (1):7787. ［7］ Rischin D, Peters LJ, O′Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase Ⅲ trial of the transtasman radiation oncology group［J］. J Clin Oncol, 2010, 28(18):2989-2995. ［8］ Lim AM, Rischin D, Fisher R, et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase Ⅲ trial［J］. Clin Cancer Res, 2012, 18(1):301-307. ［9］ Sun JD, Liu Q, Wang J, et al. Selective tumor hypoxia targeting by hypoxiaactivated prodrug TH-302 inhibits tumor growth in preclinical models of cancer［J］. Clin Cancer Res, 2012, 18(3):758-770. ［10］ Ganjoo KN, Cranmer LD, Butrynski JE, et al. A phase Ⅰ study of the safety and pharmacokinetics of the hypoxiaactivated prodrug TH302 in combination with doxorubicin in patients with advanced soft tissue sarcoma［J］. Oncology, 2011, 80(1-2):50-56. ［11］ Borad MJ, Reddy S, Bahary N, et al. TH302+ gemcitabine vs gemcitabine in patients with untreated advanced pancreatic cancer［J］. Ann Oncol, 2012, 23(9S):S224-257. ［12］ Xia Y, Choi HK, Lee K, et al. Recent advances in hypoxiainducible factor (HIF)-1 inhibitors［J］. Eur J Med Chem, 2012, 49(3):24-40. ［13］ Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxiainducible factor-1［J］. Curr Med Chem, 2011, 18(21):3168-3189. ［14］ Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxiainducible factor1alpha, EZN2968, inhibits tumor cell growth［J］. Mol Cancer Ther, 2008, 7(11):35983608. ［15］ Patnaik A, Chiorean EG, Tolcher A, et al. EZN2968, a novel hypoxiainducible factor1α (HIF1a) messenger ribonucleic acid (mRNA) antagonist: results of a phase Ⅰ, pharmacokinetic (PK), doseescalation study of daily administration in patients (pts) with advanced malignancies［J］. J Clin Oncol, 2009, 27(15S):S2564. ［16］ Palayoor ST, Mitchell JB, Cerna D, et al. PX478, an inhibitor of hypoxiainducible factor1a, enhances radiosensitivity of prostate carcinoma cells［J］. Int J Cancer, 2008, 123(10):2430-2437. ［17］ Jacoby JJ, Erez B, Korshunova MV, et al. Treatment with HIF1 antagonist PX478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice［J］. J Thorac Oncol, 2010, 5(7):940-949. ［18］ Lee K, Kim HM. A novel approach to cancer therapy using PX478 as a HIF1α inhibitor［J］. Arch Pharm Res, 2011, 34(10):1583-1585. ［19］ Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer［J］. Nat Rev Cancer, 2008, 8(11):851-864. ［20］ Nagelkerke A, Bussink J, Mujcic H, et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3arm of the unfolded protein response［J］. Breast Cancer Res, 2013, 15(1):R2. ［21］ Papandreou I, Denko NC, Olson M, et al. Identi?cation of an Ire1alpha endonuclease speci?c inhibitor with cytotoxic activity against human multiple myeloma［J］. Blood, 2011, 117(4):1311-1314. ［22］ Turkington RC, Purcell C, James CR, et al. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma［J］. Invest New Drugs, 2013, 11. ［23］ Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma［J］. Br J Haematol, 2013, 160(5):649-659. ［24］ Advani SH. Targeting mTOR pathway: A new concept in cancer Therapy［J］. Indian J Med Paediatr Oncol, 2010, 31(4):132-136. ［25］ Nishikawa T, Takaoka M, Ohara T, et al. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancerbearing mice［J］. Cancer Biol Ther, 2013, 14(3):230-236. ［26］ Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma［J］. Oncologist, 2010, 15(4):428-435.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.